Jazz Pharmaceuticals (JAZZ) Up Ahead of Phase III Study Presentation
More News related to JAZZ
- Jazz Pharmaceutical (JAZZ) options active as shares rally 10%
- Jazz Pharmaceuticals (JAZZ) Sees Upside
- Jazz Pharmaceuticals to Present at Investor Conference
- Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to FDA
- Notable Analyst Rating Changes for 11/30: X, DE, AFL, AEO Upgraded; BIDU, SWY, BKC, SVU Downgraded
- Morning Movers 11/30: PEIX, CLRT, PROV, SOMX, OTIV Higher; HPOL, MELA Lower
- Notable Mergers and Acquisitions of the Day 11/30: SYK, PPDI, CAT, VNR, CBE/FSS
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is 7% higher this morning after announcing that data from its first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented next week (October 20) during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress in Las Vegas, Nevada.
Jazz Pharmaceuticals has completed two Phase III pivotal clinical trials of JZP-6, with positive results in both studies. Jazz Pharmaceuticals is working to submit a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
